MTOR and diabetic kidney disease: Interestingly, Eid et al. (51), in a different experimental system, have shown that the pharmacological inhibition of mTOR with rapamycin decreases NOX4 activity, ROS production, and podocytes apoptosis induced by high glucose, suggesting that rapamycin may represent a therapeutic modality of diabetic kidney disease (51).